High Potency API Market 2030

Active Pharmaceutical Ingredients and High Potency API Industry

Active Pharmaceutical Ingredients and High Potency API Industry Data Book | Forecast 2030

Active Pharmaceutical Ingredients and High Potency API Industry Data Book – Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market

Grand View Research’s API and High Potency API industry databook is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.The following data points will be included in the final product offering in two reports and one sector report overview.

Access the Global Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

Active Pharmaceutical Ingredients Market Report Highlights

• Innovative APIs held the largest share of 47.07% in 2022, owing to increasing research and development activities for novel drug development and positive government initiatives

• The cardiovascular disease segment held the largest revenue share of 21.54% in 2022, attributed to the rising prevalence of target disease globally

• The synthetic API segment dominated the market with the largest revenue share of 72.6% in 2021, owing to the higher availability of raw materials and easier protocols for the synthesis of these molecules

• North America accounted for the largest revenue share of 38.80% in 2021 and is expected to maintain its lead over the forecast period. This is attributed to the rising epidemiology of cancer, along with other lifestyle-induced diseases, thus encouraging the R&D activities, thereby boosting the market growth

Order your copy of the Free Sample of “Active Pharmaceutical Ingredients and High Potency API Industry Data Book – Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030, published by Grand View Research

High Potency Active Pharmaceutical Ingredients Market

• In 2022, synthetic segment held a dominant share in the HPAPI market owing to its easier synthesis and effectiveness in treatment offered by synthetic HPAPI

• Outsourced segment is projected to grow at the fastest rate over the forecast period owing to the increasing adoption of outsourcing of HPAPI

• Innovative HPAPI segment is the highest revenue-generating segment in 2022 owing to the increased focus on R&D.

• Oncology segment dominated the overall market owing to the rising cancer incidence worldwide along with an enhanced focus on targeted therapies

• Asia Pacific is expected to witness the fastest growth during the forecast period owing to the improved manufacturing facilities and the availability of many generic HPAPI producers

Competitive Landscape

Competitive rivalry in this market is likely to be high due to increasing interest in small molecules and biologics for the treatment of chronic diseases is attracting industry players. These players have adopted strategies such as acquisitions, collaborations, and expansion of manufacturing units to strengthen their position in the market. Development of targeted therapies over the forecast period is expected to further intensify the competitive rivalry in the market. As part of strategic geographical expansion, many companies are setting up manufacturing plants in Asia Pacific region. In addition, increasing number of companies switch to contract manufacturers for APIs, which is further increasing competitive rivalry.

Some of the key players in the API and High Potency API market are Teva Pharmaceutical Industries Ltd., AbbVie, Inc., BASF SE, Boehringer Ingelheim International GmbH, CordenPharma, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Cipla, Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Sanofi, Pfizer, Inc., Viatris Inc., Albemarle Corporation, and Aurobindo Pharma.

Key market players adopting expansion strategy include Novo Nordisk, Merck KGaA, Novartis AG, Aurobindo Pharma, and Piramal Pharma. For instance, in November 2022, Novo Nordisk Invested USD 744 million for expansion of its clinical manufacturing facility in Bagsvaerd, Denmark. This strategy is adopted to increase the outreach of their products in the market and increase the availability of their products & services in diverse geographical areas.